Multiple myeloma: The (r)evolution of current therapy and a glance into the future

Abstract

Over the past 20 years, the regulatory approval of several novel agents to treat multiple myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased understanding of MM biology has led to advances in diagnosis, prognosis, and response assessment, and has informed the development of targeted and immune agents. Here we provide an overview of the recent progress in MM, and highlight the most promising research areas to further improve patient outcome in the future.